AstraZeneca Medicines  Medicines AstraZeneca Medicines  Medicines
    • My Account
    • Logout
  • en-sa
    • en-sa
    • en-uae
    • en-kw
    • en-qa
    • en-bh
    • en-om
  • Home
  • CVRM
    • CVRM
    • CKD Screening
      • CKD Screening
      • HCP Access
      • Health Authority
    • The Burden of CKD
      • The Burden of CKD
      • Impact of Early Intervention
      • Know Your Patients’ Numbers
      • Who’s at Risk?
      • How to Talk CKD With Patients
      • Underlying Mechanism of CKD
      • Resources for You and Your Patients
    • Lokelma
      • Lokelma
      • About Hyperkalaemia
      • Hyperkalaemia in different patient subsets
      • Chronic Kidney Disease
      • Haemodialysis Patients
      • Explore LOKELMA
      • Efficacy
      • Safety
      • Dosing and Administration
      • Continuing RAASi
    • BRILINTA
      • BRILINTA
      • Product Information
        • Product Information
        • Indications
        • Prescribing BRILINTA 90mg
        • Mode of Action
        • Mode of Administration
        • Contraindicatons, Warnings and precautions
      • Clinical studies
        • Clinical studies
        • PLATO
        • TREAT
        • PRACTICAL
      • Guidelines
        • Guidelines
        • ESC & ACC guidelines recommendation
      • References
    • Amyloidosis
  • Oncology
    • Oncology
    • Lung Cancer
    • GI Cancer
    • Prostate Cancer
    • Breast Cancer
      • Breast Cancer
      • HER2HUB
        • HER2HUB
        • HER2HOPE
        • HER2Know
    • Ovarian Cancer
    • Tumour Agnostic
      • Tumour Agnostic
      • HER2Know
        • HER2Know
        • IHC Atlas
        • Supporting Resources
        • IHC Knowledge Check
        • Backup IHC Atlas
        • Backup IHC Knowledge Check
        • HER2 IHC Virtual
        • HER2 Documentary
    • ENHERTU
      • ENHERTU
      • About ENHERTU
      • DESTINY-Breast03 Trial
      • Efficacy Data
      • Safety Data
      • Important Safety Information
      • Mindshare
      • Launch Event
    • Disease Awareness
      • Disease Awareness
      • Lung Cancer Awareness
      • Liver Cancer Awareness
        • Liver Cancer Awareness
        • Hepatocellular carcinoma (HCC)
        • Biliary tract cancer
    • Zoladex
      • Zoladex
      • Prostate Cancer
      • Prescribing information
        • Prescribing information
        • Early Breast Cancer
        • Advanced Breast Cancer
  • Hematology
    • Hematology
    • AZ Hematology Hub
      • AZ Hematology Hub
      • Featured Moments Videos
        • Featured Moments Videos
        • Review on Time to Progression Regimen
        • Latest Updates in Management of CLL
        • Continues Therapy Versus Time Limited Therapy
        • Mantle Cell Lymphoma
        • Critical Evaluation of BTKis in CLL
  • Respiratory
    • Respiratory
    • Asthma Impairment and Risk Questionnaire (AIRQ)
    • Breztri
      • Breztri
      • Breztri
      • Efficacy & Safety
      • Dosing & Administration
      • Device
      • Tools & Resources
      • GCC Puma Survey
  • Biologics
    • Biologics
    • EpiCentral
    • Tezspire
      • Tezspire
      • Mechanism of Disease
      • Mechanism of Action
      • Experts on Severe Asthma
      • Efficacy & Clinical Data
      • Impact on AHR & Biomarker Levels
      • Clinical Trial Designs
      • Patient Profiles
      • Safety
      • Dosing & Administration
      • Patient Support Program
  • Vaccine & Immunology
    • Vaccine & Immunology
    • COVID-19
      • COVID-19
      • Hematological Malignancy
      • ESKD
      • Solid Organ Transplant
      • Immunosuppressive
  • Rare Disease
    • Rare Disease
    • HPP Hub
      • HPP Hub
      • Strensiq Dosage wheel
    • NF1 Hub
      • NF1 Hub
      • NF1
        • NF1
        • Impact of NF1-PN
        • Diagnosis and management
  • AZ Spotlight 2024
    • AZ Spotlight 2024
    • AZ Spotlight - ERA 2024
    • AZ Spotlight - ASCO 2024
    • AZ Spotlight - EULAR 2024
    • AZ Spotlight - ESC 2024
    • AZ Spotlight - ERS 2024
  • Care Corner
  • Recorded Videos
    • Recorded Videos
    • Diabetes - Educational Videos
    • Diabetes - Speaker Led Meetings
    • Diabetes - Educational Programs
    • Cardiovascular - Educational Videos
    • Cardiovascular - Speaker Led Meetings
    • Cardiovascular - Educational Programs
    • Respiratory - Educational Videos
    • Respiratory - Speaker Led Meetings
    • Respiratory - Educational Programs
    • Oncology - Educational Videos
    • Oncology - Speaker Led Meetings
    • Oncology - Educational Programs
  • More Hide
      • My Account
      • Logout
    • en-sa
      • en-sa
      • en-uae
      • en-kw
      • en-qa
      • en-bh
      • en-om
    • About COPD
    • Breztri
    • Efficacy & Safety
    • Dosing & Administration
    • Device
    • Tools & Resources
    • PUMA Questionnaire

    Sub Navigation Links

    About COPD

    Breztri

    Efficacy & Safety

    Dosing & Administration

    Device

    Tools & Resources

    PUMA Questionnaire

     

     

    Device

     

     

     

     

     

     

     

     

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue

    AstraZeneca EduGate

    This website is intended for doctors, nurses, and pharmacists in GCC countries. Others please visit www.astrazeneca.com.

    Additional Info


    • Legal Notice and Terms of Use
    • Privacy Notice
    • Cookie Policy

    Contact AstraZeneca


    • Contact Us
    • Report Adverse Event

    Adverse events should be reported. Reporting forms and information can be found at aereporting.astrazeneca.com. Adverse events should also be reported to AstraZeneca Saudi on +966112249235 / email at ksa.ae@astrazeneca.com

    في حالة وجود أي أعراض جانبیة للأدویة الرجاء التواصل مع الهیئة العامة للغذاء والدواء عن طریق الرقم الموحد 19999

    Approval Code: Y1-0900

    For Medical information Enquires
    Website: https://contactazmedical.astrazeneca.com
    E-mail: medinfo-ksa@astrazeneca.com

    Al-Nakhla Tower - Floor 13th Ath Thumamah, Road - Al
    Sahafa District. 7198 Unit No. 20 Riyadh 13315 – 3642.
    Tel: +966 (011) 22 492 00
    Fax: +966 (011) 22 492 91

     

    Back to top